WO2009064738A9 - Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents - Google Patents
Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents Download PDFInfo
- Publication number
- WO2009064738A9 WO2009064738A9 PCT/US2008/083147 US2008083147W WO2009064738A9 WO 2009064738 A9 WO2009064738 A9 WO 2009064738A9 US 2008083147 W US2008083147 W US 2008083147W WO 2009064738 A9 WO2009064738 A9 WO 2009064738A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- combination
- breast cancer
- parp inhibitor
- tumor agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008321128A AU2008321128A1 (en) | 2007-11-12 | 2008-11-11 | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
EP08849309.3A EP2217227B1 (en) | 2007-11-12 | 2008-11-11 | Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
JP2010533334A JP2011503111A (en) | 2007-11-12 | 2008-11-11 | Treatment of breast cancer with PARP inhibitors alone or in combination with antitumor agents |
NZ586125A NZ586125A (en) | 2007-11-12 | 2008-11-11 | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
CA2705537A CA2705537A1 (en) | 2007-11-12 | 2008-11-11 | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
MX2010005222A MX2010005222A (en) | 2007-11-12 | 2008-11-11 | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents. |
RU2010123884/14A RU2480211C2 (en) | 2007-11-12 | 2008-11-11 | Method of treating breast cancer with compound of 4-iodine-3-nitrobenzamine in combination with anticancer agents |
CN2008801245719A CN101917982B (en) | 2007-11-12 | 2008-11-11 | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
TN2010000208A TN2010000208A1 (en) | 2007-11-12 | 2010-05-11 | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
IL205689A IL205689A0 (en) | 2007-11-12 | 2010-05-11 | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
EC2010010240A ECSP10010240A (en) | 2007-11-12 | 2010-06-08 | TREATMENT OF BREAST CANCER WITH A PARP INHIBITOR ONLY OR IN COMBINATION WITH ANTI-TUMOR AGENTS |
MA32906A MA31909B1 (en) | 2007-11-12 | 2010-06-11 | TREATMENT OF BREAST CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98733307P | 2007-11-12 | 2007-11-12 | |
US60/987,333 | 2007-11-12 | ||
US1236407P | 2007-12-07 | 2007-12-07 | |
US61/012,364 | 2007-12-07 | ||
US5852808P | 2008-06-03 | 2008-06-03 | |
US61/058,528 | 2008-06-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009064738A2 WO2009064738A2 (en) | 2009-05-22 |
WO2009064738A9 true WO2009064738A9 (en) | 2009-07-16 |
Family
ID=40639414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/083147 WO2009064738A2 (en) | 2007-11-12 | 2008-11-11 | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
Country Status (23)
Country | Link |
---|---|
US (3) | US7732491B2 (en) |
EP (1) | EP2217227B1 (en) |
JP (1) | JP2011503111A (en) |
KR (1) | KR20100102609A (en) |
CN (2) | CN101917982B (en) |
AR (1) | AR069291A1 (en) |
AU (1) | AU2008321128A1 (en) |
CA (1) | CA2705537A1 (en) |
CO (1) | CO6290650A2 (en) |
CR (1) | CR11485A (en) |
DO (2) | DOP2010000141A (en) |
EC (1) | ECSP10010240A (en) |
GT (1) | GT201000140A (en) |
IL (1) | IL205689A0 (en) |
MA (1) | MA31909B1 (en) |
MX (1) | MX2010005222A (en) |
NI (1) | NI201000083A (en) |
NZ (1) | NZ586125A (en) |
RU (2) | RU2480211C2 (en) |
SG (1) | SG185952A1 (en) |
TN (1) | TN2010000208A1 (en) |
TW (2) | TW200924739A (en) |
WO (1) | WO2009064738A2 (en) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2615374A1 (en) | 2005-07-18 | 2007-01-25 | Ernest Kun Kun | Treatment of cancer |
AU2007354301A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with PARP inhibitors |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
AU2007292387A1 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
CN101534836B (en) | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Use of PARP inhibition in preparing medicine for obesity |
US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
CA2662335A1 (en) * | 2006-09-05 | 2008-03-13 | Valeria Ossovskaya | Methods for designing parp inhibitors and uses thereof |
US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
AU2008321128A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
EP2217244A4 (en) * | 2007-11-12 | 2011-08-31 | Bipar Sciences Inc | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
KR20100102637A (en) * | 2007-12-07 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
WO2009100159A2 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
WO2009143611A1 (en) * | 2008-05-27 | 2009-12-03 | Oncolytics Biotech Inc. | Abrogating proinflammatory cytokine production during oncolytic reovirus therapy |
WO2010118324A2 (en) | 2009-04-09 | 2010-10-14 | Nuclea Biotechnologies, LLC | Antibodies against fatty acid synthase |
US8685891B2 (en) | 2009-08-27 | 2014-04-01 | Nuclea Biotechnologies, Inc. | Method and assay for determining FAS expression |
US8710035B2 (en) * | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
EP2558866B1 (en) * | 2010-04-15 | 2016-08-17 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
WO2011133520A1 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
ES2609931T3 (en) * | 2010-06-18 | 2017-04-25 | Myriad Genetics, Inc. | Methods and materials to evaluate the loss of heterozygosity |
WO2012012454A1 (en) * | 2010-07-19 | 2012-01-26 | Bipar Sciences, Inc. | Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan |
ES2588979T3 (en) | 2010-08-24 | 2016-11-08 | Dana-Farber Cancer Institute, Inc. | Procedures for predicting a response against cancer |
US20140315973A1 (en) * | 2010-10-07 | 2014-10-23 | Agency For Science, Technology And Research | Parp-1 inhibitors |
AU2011325809B2 (en) | 2010-11-05 | 2015-09-24 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Benzamide derivative with anticancer activity and preparation method and use thereof |
WO2012106559A1 (en) * | 2011-02-02 | 2012-08-09 | Translational Genomics Research Institute | Biomarkers and methods of use thereof |
US9314473B2 (en) * | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
WO2012155063A1 (en) * | 2011-05-11 | 2012-11-15 | Synta Pharmaceuticals Corp. | Treating cancer with an hsp90 inhibitory compound |
US9181553B2 (en) | 2011-06-06 | 2015-11-10 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Method of treatment of breast cancers over-expressing the SHP2 signature genes |
EP3693473A1 (en) | 2011-06-17 | 2020-08-12 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
CN110075316A (en) * | 2011-08-15 | 2019-08-02 | 吉安特科技股份有限公司 | The transportation system and its application method of selectively targeted cancer cell |
FI20115876A0 (en) * | 2011-09-06 | 2011-09-06 | Turun Yliopisto | Combination therapy |
JP2014526564A (en) * | 2011-09-26 | 2014-10-06 | セルジーン コーポレイション | Combination therapy for chemotherapy-resistant cancer |
CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
EP2776025A1 (en) | 2011-11-02 | 2014-09-17 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
AU2012339679A1 (en) | 2011-11-14 | 2014-06-12 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with BRAF inhibitors |
JP6325453B2 (en) | 2011-12-21 | 2018-05-16 | ミリアド・ジェネティックス・インコーポレイテッド | Methods and materials for assessing loss of heterozygosity |
US8889707B2 (en) * | 2012-02-08 | 2014-11-18 | Malka COHEN-ARMON | Treatment of addiction |
NZ628813A (en) | 2012-02-23 | 2015-10-30 | Univ Denmark Tech Dtu | Methods for predicting anti-cancer response |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
MX369768B (en) * | 2012-06-01 | 2019-11-21 | Berg Llc | Treatment of solid tumors using coenzyme q10. |
AU2013273466B2 (en) | 2012-06-07 | 2018-11-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
WO2014160080A1 (en) | 2013-03-14 | 2014-10-02 | Children's Medical Center Corporation | Cancer diagnosis, treatment selection and treatment |
US20160184356A1 (en) * | 2013-03-15 | 2016-06-30 | Ke Jian Jim Liu | Arsenic-based treatment of cancers and inflammatory disorders |
WO2014150840A1 (en) * | 2013-03-15 | 2014-09-25 | Medimmune, Llc | Methods of treating breast cancer |
WO2014168991A1 (en) | 2013-04-09 | 2014-10-16 | The Board Of Trustees Of The University Of Illinois | Tumor-selective combination therapy |
CA2931181C (en) | 2013-12-09 | 2023-01-24 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
AU2015206667B2 (en) * | 2014-01-14 | 2020-05-14 | Nektar Therapeutics | Combination-based treatment method |
EP3137076A4 (en) * | 2014-05-02 | 2017-12-06 | Emory University | Selective chemotherapy treatments and diagnostic methods related thereto |
US9303069B2 (en) * | 2014-05-05 | 2016-04-05 | University Of Mississippi Medical Center | Peptides for treating cancer |
WO2016025958A1 (en) | 2014-08-15 | 2016-02-18 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
JP6735277B2 (en) * | 2014-12-12 | 2020-08-05 | メディベイション プロステイト セラピューティクス エルエルシー | Methods for predicting response to breast cancer therapeutics and methods for treating breast cancer |
EP3265560B1 (en) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologous recombination factors |
IL256203B (en) * | 2015-06-12 | 2022-09-01 | Genea Ip Holdings Pty Ltd | Method and system for patient and biological sample identification and tracking |
JP7048505B2 (en) * | 2015-11-10 | 2022-04-05 | パラクリン セラピューティクス エービー | Treatment of ER-negative breast cancer with PDGF-CC inhibitors and antiestrogens |
WO2017174879A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Oulu | Compounds for use in the treatment of cancer |
US11890292B2 (en) | 2017-02-27 | 2024-02-06 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
CN110337450B (en) | 2017-03-02 | 2023-07-25 | 豪夫迈·罗氏有限公司 | Adjuvant therapy of HER2 positive breast cancer |
WO2018170457A1 (en) * | 2017-03-17 | 2018-09-20 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
WO2018183947A1 (en) | 2017-03-31 | 2018-10-04 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
JP7405616B2 (en) * | 2017-04-07 | 2023-12-26 | タンボ・インコーポレイテッド | bioorthogonal compositions |
CA3063201A1 (en) * | 2017-05-09 | 2018-11-15 | Tesaro, Inc. | Combination therapies for treating cancer |
WO2018213732A1 (en) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
EP3655418A4 (en) | 2017-06-22 | 2021-05-19 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
US20210108199A1 (en) * | 2017-09-06 | 2021-04-15 | The Trustees Of Columbia University In The City Of New York | Treatment for aggressive cancers by targeting C9ORF72 |
EP3687501A4 (en) | 2017-09-29 | 2021-06-23 | Triact Therapeutics, Inc. | Iniparib formulations and uses thereof |
EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | Combination therapies for treating cancer |
WO2019071123A1 (en) * | 2017-10-06 | 2019-04-11 | Tesaro, Inc. | Combination therapies and uses thereof |
EP3709981A4 (en) * | 2017-11-15 | 2021-08-11 | The Regents of the University of California | Methods of treating extrachromosomal dna expressing cancers |
CN111867587A (en) * | 2018-02-12 | 2020-10-30 | 信达制药公司 | Thioredoxin reductase inhibitors for the treatment of cancer |
US10953209B2 (en) * | 2018-03-28 | 2021-03-23 | Board Of Regents Of The University Of Texas System | Treating tumors using TTFields combined with a PARP inhibitor |
MA52642A (en) * | 2018-05-14 | 2021-03-24 | Nuvation Bio Inc | COMPOUNDS TARGETING NUCLEAR ANTI-CANCER HORMONAL RECEPTORS |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
US11464764B2 (en) | 2018-12-19 | 2022-10-11 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
KR20210118971A (en) | 2019-02-22 | 2021-10-01 | 코어셉트 쎄라퓨틱스 인코포레이티드 | Therapeutic use of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
WO2020232133A1 (en) * | 2019-05-14 | 2020-11-19 | Georgetown University | Methods of treating gastrointestinal cancers and tumors thereof using combination therapy |
CN113811333B (en) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | Compounds targeting anti-cancer nuclear hormone receptors |
WO2021137932A1 (en) * | 2019-11-04 | 2021-07-08 | Faraday Pharmaceuticals, Inc. | Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity |
KR20220123064A (en) * | 2019-12-31 | 2022-09-05 | 킨네이트 바이오파마 인크. | Cancer treatment with CDK12/13 inhibitors |
CN111362828A (en) * | 2020-03-30 | 2020-07-03 | 山西医科大学 | A kind of18F-labeled fluoropropionylated ornithine as well as preparation method and application thereof |
US11834458B2 (en) | 2021-03-23 | 2023-12-05 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
US20230190841A1 (en) * | 2021-12-22 | 2023-06-22 | Laura Mann Kevehazi | Herbal composition for breast cancer prevention |
Family Cites Families (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2669583A (en) * | 1954-02-16 | X-amroo-zralkoxbbenzamdjes | ||
US2006735A (en) * | 1932-11-17 | 1935-07-02 | Gen Aniline Works Inc | Nitro-aryl amino-aryl amines |
NL247377A (en) * | 1957-11-25 | |||
US3161564A (en) | 1960-10-03 | 1964-12-15 | Salsbury S Lab Dr | Veterinary composition containing halo-nitro-benzamides and methods of using same |
US3228833A (en) * | 1962-12-17 | 1966-01-11 | Sterling Drug Inc | Anticoccidial compositions and methods of using same |
AR204004A1 (en) | 1973-04-02 | 1975-11-12 | Lilly Co Eli | PROCEDURES FOR PREPARING VINBLASTIN LEUROSIDINE AND LEUROCRISTINE DERIVATIVES |
FR2456731A1 (en) | 1979-05-16 | 1980-12-12 | Choay Sa | Guanidino and amino benzoate(s) and phenyl sulphonate(s) - and related cpds. inhibit protease(s) and have bacteriostatic and fungistatic activity |
JPS6019790A (en) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | Novel camptothecin derivative |
US5032617A (en) * | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
US5041653A (en) | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
US5215738A (en) * | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
JP2534631B2 (en) * | 1986-01-17 | 1996-09-18 | プリベンティブ メディシン インスティテュート | Tests for measuring susceptibility to or susceptibility to DNA related diseases |
US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
US5223608A (en) * | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
US4923885A (en) * | 1988-08-19 | 1990-05-08 | Merck & Co., Inc. | 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents |
US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
WO1991004663A1 (en) | 1989-09-26 | 1991-04-18 | The Regents Of The University Of California | 6-amino-1,2-benzopyrones useful for treatment of viral diseases |
US5719151A (en) * | 1990-05-04 | 1998-02-17 | Shall; Sydney | Substituted benzene compounds |
US5633282A (en) * | 1990-05-25 | 1997-05-27 | British Technology Group Limited | Inhibition of viral infection |
US5631038A (en) * | 1990-06-01 | 1997-05-20 | Bioresearch, Inc. | Specific eatable taste modifiers |
US5232735A (en) | 1990-06-01 | 1993-08-03 | Bioresearch, Inc. | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers |
US5637618A (en) * | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
ES2137932T3 (en) * | 1990-09-28 | 2000-01-01 | Smithkline Beecham Corp | PROCEDURE FOR THE PREPARATION OF WATER-SOLUBLE CAMPTOTECHE ANALOGS, AS WELL AS THE 10-HYDROXY-11-ALCOXI-6-CAMPTOTINE COMPOUNDS. |
US5484951A (en) * | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
US5200524A (en) * | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
US5247089A (en) | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
US5191082A (en) * | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
US5162532A (en) | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
US5243050A (en) | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
EP0533902A1 (en) | 1991-04-10 | 1993-03-31 | Octamer, Inc. | A method for inhibition of retroviral replication |
US5877185A (en) * | 1991-10-22 | 1999-03-02 | Octamer, Inc. | Synergistic compositions useful as anti-tumor agents |
US5473074A (en) | 1991-10-22 | 1995-12-05 | Octamer, Incorporated | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54 |
US5516941A (en) * | 1991-10-22 | 1996-05-14 | Octamer, Inc. | Specific inactivators of "retroviral" (asymmetric) zinc fingers |
US5482975A (en) * | 1991-10-22 | 1996-01-09 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents |
US5753674A (en) * | 1991-10-22 | 1998-05-19 | Octamer, Inc. | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents |
US5464871A (en) | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
ES2309119T3 (en) | 1992-10-28 | 2008-12-16 | Genentech, Inc. | USE OF ANTIGONISTS OF THE VEGF CELLULAR GROWTH FACTOR. |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
US5783599A (en) * | 1993-02-24 | 1998-07-21 | Octamer Inc | Methods of treating cancer and viral infections with 5-iodo-6-amino-and 5-iodo-6-nitroso-1 2-benzopyrones |
JP3025602B2 (en) * | 1993-05-21 | 2000-03-27 | デビオファーム エス.アー. | Method for producing optically high purity cis-oxalate (trans-l-l, 2-cyclohexanediamine) platinum (II) complex |
DZ1781A1 (en) | 1993-05-21 | 2002-02-17 | Radopah Ltd | Arylating agents. |
US6015792A (en) * | 1993-05-26 | 2000-01-18 | Bioresearch, Inc. | Specific eatable taste modifiers |
US6008250A (en) | 1993-05-26 | 1999-12-28 | Bioresearch, Inc. | Specific eatable taste modifiers |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
KR100447539B1 (en) | 1995-08-02 | 2004-11-10 | 뉴캐슬 유니버시티 벤처스 리미티드 | Benzoimidazole compounds, pharmaceutical compositions comprising them and methods of treatment using the same |
JP3154399B2 (en) | 1996-07-04 | 2001-04-09 | デビオファーム エス.アー. | Method for producing platinum compound |
RU2103260C1 (en) * | 1996-04-26 | 1998-01-27 | Государственный научный центр Российской Федерации "НИОПИК" | Method for production of 4-nitrobenzamide |
US5837729A (en) | 1996-04-26 | 1998-11-17 | Metatron, Inc. | Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof |
US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
US20050287120A1 (en) | 1997-03-21 | 2005-12-29 | Fisher Paul B | Cancer - targeted viral vectors |
AU741382B2 (en) * | 1997-03-26 | 2001-11-29 | Large Scale Biology Corporation | Di-aryl ethers and their derivatives as anti-cancer agents |
US5908861A (en) | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
US6514983B1 (en) * | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
US6235748B1 (en) * | 1997-09-03 | 2001-05-22 | Guilford Pharmaceuticals Inc. | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6121278A (en) | 1997-09-03 | 2000-09-19 | Guilford Pharmaceuticals, Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
US6426415B1 (en) * | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
US5922775A (en) | 1997-10-23 | 1999-07-13 | Octamer, Inc. | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
US6395749B1 (en) * | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
JP2002515488A (en) | 1998-05-15 | 2002-05-28 | ギルフォード ファーマシューティカルズ インコーポレイテッド | Carboxamide compounds, compositions, and methods for inhibiting PARP activity |
US6380193B1 (en) * | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
CO5070700A1 (en) | 1998-06-05 | 2001-08-28 | Basf Ag | NOVELTY GENES OF (ADP-RIBOSA) POLYMERASE |
CN1331682A (en) | 1998-11-03 | 2002-01-16 | 巴斯福股份公司 | Substituted 2-phenylbenzimidazoles, prodn. thereof and their use |
SK285529B6 (en) | 1998-11-27 | 2007-03-01 | Basf Aktiengesellschaft | Substituted benzimidazoles, pharmaceutical composition containing them and their use as PARP inhibitors |
JP3552934B2 (en) | 1998-12-24 | 2004-08-11 | セントラル硝子株式会社 | Method for producing benzoic acid amides |
US6326517B1 (en) | 1998-12-10 | 2001-12-04 | Central Glass Company, Limited | Method of producing benzamides |
US6201020B1 (en) * | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
US6387902B1 (en) * | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
EP1140936B1 (en) | 1999-01-11 | 2004-03-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
AU3076700A (en) * | 1999-01-26 | 2000-08-18 | Ono Pharmaceutical Co. Ltd. | 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient |
US6423696B1 (en) * | 1999-04-16 | 2002-07-23 | The United States Of America, As Represented By The Department Of Health & Human Services | Inhibition of arylamine N-acetyl transferase |
DE19921567A1 (en) * | 1999-05-11 | 2000-11-16 | Basf Ag | Use of phthalazine derivatives |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
ECSP003637A (en) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | TRICYCLE POLY INHIBITORS (ADP-RIBOSA) POLYMERASES |
US6803457B1 (en) | 1999-09-30 | 2004-10-12 | Pfizer, Inc. | Compounds for the treatment of ischemia |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
US6277990B1 (en) | 1999-12-07 | 2001-08-21 | Inotek Corporation | Substituted phenanthridinones and methods of use thereof |
US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
AU2001264595A1 (en) * | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
ITMI20002358A1 (en) * | 2000-10-31 | 2002-05-01 | Flavio Moroni | TIENO DERIVATIVES, 2, 3-C | ISOCHINOLIN-3-ONE AS INHIBITORS OF POLY (DP-RIBOSE) POLYMERASE |
AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
US20040053888A1 (en) | 2001-01-04 | 2004-03-18 | Norio Suzuki | Cyclodextrin-containing pharmaceutical preparation |
US20020164633A1 (en) | 2001-04-20 | 2002-11-07 | Inotek Pharmaceuticals Corporation | Cell-based assay for detecting activation of poly (ADP-ribose) polymerase |
ES2282410T3 (en) | 2001-05-08 | 2007-10-16 | Kudos Pharmaceuticals Limited | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS |
WO2003007955A2 (en) | 2001-07-20 | 2003-01-30 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
NZ531245A (en) | 2001-08-15 | 2005-09-30 | Icos Corp | 2H-phthalazin-1-ones and methods for use thereof |
US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
OA12794A (en) | 2002-03-26 | 2006-07-10 | Banyu Pharma Co Ltd | Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent. |
AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
US20040034078A1 (en) * | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
PA8578001A1 (en) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | THERAPEUTIC COMBINATIONS OF ERB B QUINASA INHIBITORS AND ANTINEOPLASIC THERAPIES |
CA2505520C (en) | 2002-11-06 | 2012-07-17 | Azaya Therapeutics, Inc. | Protein-stabilized liposomal formulations of pharmaceutical agents |
BRPI0408996A (en) | 2003-03-31 | 2006-03-28 | Pfizer | skirt of tricyclic poly (adpp-ribose) polymerase inhibitors |
JP2007535895A (en) * | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | Fully human antibody against human insulin-like growth factor-1 receptor |
EP1633362B1 (en) * | 2003-05-28 | 2012-09-26 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for inhibiting parp |
US20050004038A1 (en) * | 2003-06-27 | 2005-01-06 | Lyon Robert P. | Bivalent inhibitors of Glutathione-S-Transferases |
US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
US20050026933A1 (en) * | 2003-08-01 | 2005-02-03 | Wyeth Holdings Corporation | Use of a combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer |
WO2005023246A1 (en) * | 2003-09-04 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp) |
WO2005023765A1 (en) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
US7855207B2 (en) | 2003-11-20 | 2010-12-21 | Janssen Pharmaceutica, Nv | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors |
BRPI0416817A (en) | 2003-11-20 | 2007-03-06 | Janssen Pharmaceutica Nv | Substituted 2-quinolinones and 7-phenylalkyl-2-quinoxalinones as poly (adp-ribose) polymerase inhibitors |
PT1684736E (en) | 2003-12-01 | 2011-11-10 | Cancer Res Inst | Dna damage repair inhibitors for treatment of cancer |
NZ547193A (en) | 2003-12-05 | 2010-03-26 | Janssen Pharmaceutica Nv | 6-Substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
US7652014B2 (en) | 2003-12-10 | 2010-01-26 | Janssen Pharmaceutica | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
US7439031B2 (en) * | 2003-12-15 | 2008-10-21 | The Trustees Of The University Of Pennsylvania | Method of identifying compounds that induce cell death by necrosis |
US7680864B2 (en) | 2004-03-02 | 2010-03-16 | Intel Corporation | Method and apparatus for managing access to stored objects based on retention policy |
PE20060285A1 (en) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | PYRIDONES SUBSTITUTE AS POL (ADP-RIBOSA) -POLYMERASE (PARP) INHIBITORS |
JP2005336083A (en) | 2004-05-26 | 2005-12-08 | Sumitomo Chemical Co Ltd | Method for producing aromatic amino compound |
AU2005259190B2 (en) | 2004-06-30 | 2011-05-12 | Janssen Pharmaceutica N.V. | Quinazolinedione derivatives as PARP inhibitors |
MXPA06014542A (en) | 2004-06-30 | 2007-03-23 | Janssen Pharmaceutica Nv | Phthalazine derivatives as parp inhibitors. |
MXPA06014933A (en) | 2004-06-30 | 2007-02-28 | Janssen Pharmaceutica Nv | Substituted 2-alkyl quinazolinone derivatives as parp inhibitors. |
US20060035890A1 (en) | 2004-08-10 | 2006-02-16 | Amit Banerjee | Compounds and methods for the treatment of ubiquitin conjugating disorders |
GB0419072D0 (en) * | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
CA2581025C (en) * | 2004-09-22 | 2011-06-07 | Pfizer Inc. | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
JP2008513435A (en) * | 2004-09-22 | 2008-05-01 | ファイザー・インク | Therapeutic composition comprising a poly (ADP-ribose) polymerase inhibitor |
WO2006044687A2 (en) * | 2004-10-15 | 2006-04-27 | Takeda San Diego, Inc. | Kinase inhibitors |
DE102004050196A1 (en) | 2004-10-15 | 2006-04-20 | Sanofi-Aventis Deutschland Gmbh | Substituted 2-pyridone derivatives, process for their preparation and their use as medicaments |
US20060094676A1 (en) * | 2004-10-29 | 2006-05-04 | Ronit Lahav | Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
EP1828165B1 (en) | 2004-10-29 | 2013-03-20 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
CN1768733A (en) | 2004-11-02 | 2006-05-10 | 上海富海科申药业有限公司 | Application of aromatic nitro compound in preparation of medicine for treating AIDS |
CN1768732A (en) | 2004-11-02 | 2006-05-10 | 上海富海科申药业有限公司 | Application of aromatic nitro compound in preparation of medicine for treating tumor |
US20070157330A1 (en) * | 2004-12-07 | 2007-07-05 | Min Wu | Reconstituted human breast tumor model |
GB0428111D0 (en) | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
WO2006135873A2 (en) * | 2005-06-10 | 2006-12-21 | Bipar Sciences, Inc. | Parp modulators and treatment of cancer |
CA2615374A1 (en) * | 2005-07-18 | 2007-01-25 | Ernest Kun Kun | Treatment of cancer |
CN101316834A (en) * | 2005-09-29 | 2008-12-03 | 艾博特公司 | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent PARP inhibitors |
CN101370497B (en) * | 2006-01-17 | 2010-11-17 | 雅培制药有限公司 | Combination product with PARP inhibitors and cell toxin and its uses |
US20080293795A1 (en) | 2006-01-17 | 2008-11-27 | Abbott Laboratories | Combination therapy with parp inhibitors |
EP3056196A1 (en) | 2006-03-22 | 2016-08-17 | SynCore Biotechnology CO., LTD | Treatment of triple receptor negative breast cancer |
CA2647545C (en) * | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
AU2007354301A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with PARP inhibitors |
US20080262062A1 (en) | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
DE102006037399A1 (en) * | 2006-08-10 | 2008-02-14 | Archimica Gmbh | Process for the preparation of arylamines |
AU2007292387A1 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
CA2662335A1 (en) * | 2006-09-05 | 2008-03-13 | Valeria Ossovskaya | Methods for designing parp inhibitors and uses thereof |
CN101534836B (en) * | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Use of PARP inhibition in preparing medicine for obesity |
US7538252B2 (en) * | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
CN101190211B (en) | 2006-11-23 | 2011-08-10 | 上海富海科申药业有限公司 | Application of aromatic nitro compound in preparing medicine for treating virus hepatitis |
PL2805945T3 (en) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors |
WO2008089272A1 (en) | 2007-01-16 | 2008-07-24 | Bipar Sciences, Inc. | Formulations for cancer treatment |
SI2134691T1 (en) | 2007-03-08 | 2012-06-29 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp and tank inhibitors |
EP2211854A4 (en) * | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors |
AU2008321128A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
EP2217244A4 (en) | 2007-11-12 | 2011-08-31 | Bipar Sciences Inc | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
KR20100102637A (en) * | 2007-12-07 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
-
2008
- 2008-11-11 AU AU2008321128A patent/AU2008321128A1/en not_active Withdrawn
- 2008-11-11 JP JP2010533334A patent/JP2011503111A/en not_active Abandoned
- 2008-11-11 WO PCT/US2008/083147 patent/WO2009064738A2/en active Application Filing
- 2008-11-11 CN CN2008801245719A patent/CN101917982B/en not_active Withdrawn - After Issue
- 2008-11-11 SG SG2012081568A patent/SG185952A1/en unknown
- 2008-11-11 CA CA2705537A patent/CA2705537A1/en not_active Withdrawn
- 2008-11-11 EP EP08849309.3A patent/EP2217227B1/en active Active
- 2008-11-11 MX MX2010005222A patent/MX2010005222A/en active IP Right Grant
- 2008-11-11 KR KR1020107013013A patent/KR20100102609A/en not_active Application Discontinuation
- 2008-11-11 RU RU2010123884/14A patent/RU2480211C2/en not_active IP Right Cessation
- 2008-11-11 US US12/269,024 patent/US7732491B2/en not_active Expired - Fee Related
- 2008-11-11 NZ NZ586125A patent/NZ586125A/en not_active IP Right Cessation
- 2008-11-11 CN CN2013100532333A patent/CN103169973A/en not_active Withdrawn
- 2008-11-12 TW TW097143777A patent/TW200924739A/en unknown
- 2008-11-12 AR ARP080104935A patent/AR069291A1/en unknown
- 2008-11-12 TW TW101129769A patent/TW201249430A/en unknown
-
2009
- 2009-07-01 US US12/496,593 patent/US20100003192A1/en not_active Abandoned
-
2010
- 2010-05-11 NI NI201000083A patent/NI201000083A/en unknown
- 2010-05-11 TN TN2010000208A patent/TN2010000208A1/en unknown
- 2010-05-11 GT GT201000140A patent/GT201000140A/en unknown
- 2010-05-11 IL IL205689A patent/IL205689A0/en unknown
- 2010-05-12 DO DO2010000141A patent/DOP2010000141A/en unknown
- 2010-06-08 EC EC2010010240A patent/ECSP10010240A/en unknown
- 2010-06-10 CR CR11485A patent/CR11485A/en not_active Application Discontinuation
- 2010-06-11 CO CO10070938A patent/CO6290650A2/en not_active Application Discontinuation
- 2010-06-11 MA MA32906A patent/MA31909B1/en unknown
-
2012
- 2012-03-26 US US13/430,475 patent/US20120269861A1/en not_active Abandoned
- 2012-11-16 DO DO2012000291A patent/DOP2012000291A/en unknown
- 2012-12-13 RU RU2012153963/14A patent/RU2012153963A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009064738A9 (en) | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
IL205633A0 (en) | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
PL2139483T3 (en) | Combination therapies comprising a quinoxaline inhibitor of pi3k-alpha for use in the treatment of cancer | |
ZA200807934B (en) | Cancer treatments | |
ZA201004403B (en) | Therapeutic cancer treatments | |
EP2393364A4 (en) | Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor | |
IL206209A0 (en) | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors | |
IL195731A0 (en) | Pyrimidine derivatives useful in the treatment of cancer | |
IL197315A0 (en) | Treatment of cancer | |
HK1136822A1 (en) | Therapeutic compounds and their use in cancer | |
SI2338487T1 (en) | Combination therapy with PARP inhibitors | |
ZA200905159B (en) | Combination of LBH589 with other therapeutic agents for treating cancer | |
PT2101731T (en) | Endoxifen for use in the treatment of cancer | |
EP1962839A4 (en) | Administration of mntor inhibitor to treat patients with cancer | |
EP2211854A4 (en) | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors | |
GB2462715B (en) | Imidazole derivatives that induce apoptosis and their therapeutic uses | |
IL206189A0 (en) | Compound for use in the treatment of cancer | |
EP2056839A4 (en) | Combination approaches to cancer treatment | |
EP2224932A4 (en) | Cancer treatment using cox-2 inhibitor and antimetabolite combinations | |
GB0710871D0 (en) | Cancer treatment | |
GB0600903D0 (en) | Treatment of cancer | |
ZA200810524B (en) | Pyrimidine derivatives useful in the treatment of cancer | |
GB0622581D0 (en) | Treatment of cancer | |
GB0712513D0 (en) | Treatment of cancer | |
GB0618199D0 (en) | Cancer treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880124571.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08849309 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010050758 Country of ref document: EG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010533334 Country of ref document: JP Ref document number: 205689 Country of ref document: IL Ref document number: 2705537 Country of ref document: CA Ref document number: 12010501041 Country of ref document: PH Ref document number: MX/A/2010/005222 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 1001080 Country of ref document: KE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008849309 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3481/CHENP/2010 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201011485 Country of ref document: CR Ref document number: CR2010-011485 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 20107013013 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008321128 Country of ref document: AU Ref document number: 586125 Country of ref document: NZ Ref document number: 10070938 Country of ref document: CO Ref document number: 13104695 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201007216 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010123884 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PI 2010002168 Country of ref document: MY |
|
ENP | Entry into the national phase |
Ref document number: 2008321128 Country of ref document: AU Date of ref document: 20081111 Kind code of ref document: A |